This conclusion is supported by prior findings showing that the level of Becn1 is significantly reduced in human AD brains compared with non-AD controls, and that the reduction in the Becn1 level in transgenic APP-overexpressing APP+Becn+/− mice increased Aβ accumulation in neuronal cells [134]. This evidence concerns the gene BECN1 and Alzheimer disease.